Results 311 to 320 of about 457,600 (353)
Some of the next articles are maybe not open access.
2016
Breast cancer is the most common cancer in women worldwide. Although various subgroups are defined according to the expression of hormones and ErbB family receptors, it is well known that this disease is more heterogeneous than its classification system suggests.
Cakar B., Göker E.
openaire +2 more sources
Breast cancer is the most common cancer in women worldwide. Although various subgroups are defined according to the expression of hormones and ErbB family receptors, it is well known that this disease is more heterogeneous than its classification system suggests.
Cakar B., Göker E.
openaire +2 more sources
Receptor tyrosine kinase inhibitors in cancer
Cellular and Molecular Life Sciences, 2023Targeted therapy is a new cancer treatment approach, involving drugs that particularly target specific proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are involved in promoting growth and proliferation, Therefore inhibiting these proteins could impede cancer progression.
Nasim, Ebrahimi +11 more
openaire +2 more sources
Tyrosine kinase inhibitors and the thyroid
Best Practice & Research Clinical Endocrinology & Metabolism, 2009Protein tyrosine kinase inhibitors (TKIs) have emerged as significant targets for novel cancer therapies. For patients with differentiated or medullary carcinomas unresponsive to conventional treatments, multiple novel therapies primarily targeting angiogenesis have entered clinical trials.
openaire +2 more sources
Bulletin du cancer, 2012
Membrane receptors with tyrosine kinase activity and cytoplasmic tyrosine kinases have emerged as important potential targets in oncology. Starting from basic structures such as anilino-quinazoline, numerous compounds have been synthesised, with the help of tyrosine kinase crystallography, which has allowed to optimise protein-ligand interactions.
+5 more sources
Membrane receptors with tyrosine kinase activity and cytoplasmic tyrosine kinases have emerged as important potential targets in oncology. Starting from basic structures such as anilino-quinazoline, numerous compounds have been synthesised, with the help of tyrosine kinase crystallography, which has allowed to optimise protein-ligand interactions.
+5 more sources
Inhibitors of the insulin receptor tyrosine kinase
Pharmacology & Therapeutics, 1994Insulin is a polypeptide hormone consisting of 51 amino acids. Insulin promotes a variety of anabolic enzymatic pathways and inhibits many catabolic enzymatic pathways involved in energy storage, as well as in synthesis of structural tissue proteins.
P R, Srinivas, G, Grunberger
openaire +2 more sources
Tyrosine Kinase Inhibitors in Pediatric Malignancies
Cancer Investigation, 2007Tyrosine kinase inhibitors have been used to treat adult cancers for over a decade. Since the discovery of imatinib mesylate (STI-571, Gleevec; Novartis), tyrosine kinase inhibitors have ushered in a new age of targeted therapy. Although the United States Food and Drug Administration has approved several kinase inhibitors for use in adult cancers ...
Jeffrey M, Skolnik, Peter C, Adamson
openaire +2 more sources
Tyrosine kinase inhibitor induced pancreatitis
Journal of Oncology Pharmacy Practice, 2012Sorafenib and sunitinib are oral tyrosine kinase inhibitors, commonly used in the treatment of metastatic renal cell carcinoma. Known adverse events associated with tyrosine kinase inhibitors include hypertension and palmarplantar erythrodysesthesia. We report two cases of acute pancreatitis associated with tyrosine kinase inhibitors.
Adrienne, Sevin +2 more
openaire +2 more sources
Seminars in cancer biology, 1993
Tyrosine kinases are associated with the cytoplasmic domains of growth factor receptors as well as oncoproteins and many have the potential to cause transformation if mutated or hyperexpressed. Tyrosine kinases therefore represent an excellent target for the development of cancer drugs.
P, Workman, V G, Brunton, D J, Robins
openaire +1 more source
Tyrosine kinases are associated with the cytoplasmic domains of growth factor receptors as well as oncoproteins and many have the potential to cause transformation if mutated or hyperexpressed. Tyrosine kinases therefore represent an excellent target for the development of cancer drugs.
P, Workman, V G, Brunton, D J, Robins
openaire +1 more source
Are catechins natural tyrosine kinase inhibitors?
Drug News & Perspectives, 2002Enhanced activity of tyrosine kinase receptors (RTKs) has been implicated as a contributing factor in the development of malignant and nonmalignant proliferative diseases such as cancer and atherosclerosis. Several growth factors traducing mitogenic signals through RTKs are implicated in the development of tumor and cardiovascular diseases.
Agapios, Sachinidis, Jurgen, Hescheler
openaire +2 more sources
Cardiovascular toxicity of tyrosine kinase inhibitors
Expert Opinion on Drug Safety, 2013Small-molecule tyrosine kinase inhibitors (TKIs) have revolutionized the management of many malignancies. However, they also have been shown to be associated with a certain degree of cardiovascular side effects that are often reversible.As the number of new TKIs continues to grow, it is expected that clinicians will be facing the challenge of early ...
Elie, Mouhayar +2 more
openaire +2 more sources